Direct oral anticoagulants vs. warfarin for left ventricular thrombus

AIMS: Left ventricular (LV) thrombus carries a high risk of death and systemic embolism. While warfarin has been the standard treatment, evidence comparing direct oral anticoagulants (DOACs) with warfarin in this setting remains limited. This study aimed to compare real-world, risk-adjusted outcomes of DOAC vs. warfarin use in patients with LV thrombus. METHODS AND RESULTS: We conducted a retrospective cohort analysis using the TriNetX research network database. Adults (≥18 years) with echocardiographically confirmed LV thrombus from 2016 to 2022 were included. Patients with atrial fibrillation/flutter, venous thromboembolism, end-stage renal disease, mechanical/bioprosthetic valves, or therapy switch during follow-up were excluded. Propensity score matching (1:1) was used to balance covariates. The primary outcome was a composite of all-cause mortality and stroke/transient ischaemic attack at 30 days and 1 year. Secondary outcomes included major bleeding and LV thrombus resolution. Of 2488 eligible patients (DOAC: 950; warfarin: 1538), 945 matched pairs were analysed with all baseline covariates balanced. In the DOAC group, 74% received apixaban and 26% rivaroxaban. At 30 days and 1 year, the composite outcome did not differ significantly between DOAC and warfarin [13.3% vs. 15%; matched hazard ratio (HR): 0.90, P = 0.41, and 23.8% vs. 26.7%; matched HR: 0.93, P = 0.46, respectively]. Major bleeding rates were similar at 30 days and 1 year (1.18% vs. 1.54%; matched HR: 0.77, P = 0.54, and 4.8% vs. 4.7%; matched HR: 1.13, P = 0.58, respectively). Thrombus resolution at 6 months occurred in ∼81% of patients with follow-up imaging, with no difference by treatment group. CONCLUSION: In a large propensity-matched cohort, DOACs and warfarin demonstrated comparable effectiveness and safety for LV thrombus management, supporting DOACs as a reasonable alternative.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore cómo esta investigación se conecta con la práctica clínica

More peer-reviewed studies in Ensayos clínicos.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Wound healing potential of bark paste of Pongamia pinnata along with hirudotherapy: A case report — Balasooriya D, Karunarathna C, Uluwaduge I (2021)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Study on the effect of medicinal leech therapy (Hirudo medicinalis) on full-thickness excisional wound healing in the animal model — Zakian A et al. (2022)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• The duration of rest and feeding greatly affects the re-breeding of ectoparasites: Hirudo verbana, Hirudo medicinalis and Hirudo orientalis — Aminov R, Frolov A, Aminova A (2022)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)

Browse all ASH-analysed research →